Targeting PI3K and mTORC2 in metastatic renal cell carcinoma: new strategies for overcoming resistance to VEGFR and mTORC1 inhibitors.
about
Therapeutic challenges in renal cell carcinomaThe PI3K/AKT Pathway and Renal Cell CarcinomaKilling me softly--future challenges in apoptosis researchSphaeropsidin A shows promising activity against drug-resistant cancer cells by targeting regulatory volume increaseTAK-228 (formerly MLN0128), an investigational dual TORC1/2 inhibitor plus paclitaxel, with/without trastuzumab, in patients with advanced solid malignancies.Reprogramming induced by isoliquiritigenin diminishes melanoma cachexia through mTORC2-AKT-GSK3β signalingMammalian Target of Rapamycin Inhibitors Resistance Mechanisms in Clear Cell Renal Cell Carcinoma.Mechanisms of Acquired Resistance to Tyrosine Kinase Inhibitors in Clear - Cell Renal Cell Carcinoma (ccRCC)Tailoring mTOR-based therapy: molecular evidence and clinical challenges.Clinically significant association between the maximum standardized uptake value on 18F-FDG PET and expression of phosphorylated Akt and S6 kinase for prediction of the biological characteristics of renal cell cancerDual PI3K/mTOR Inhibitors Induce Rapid Overactivation of the MEK/ERK Pathway in Human Pancreatic Cancer Cells through Suppression of mTORC2.Radio-sensitization effect of an mTOR inhibitor, temsirolimus, on lung adenocarcinoma A549 cells under normoxic and hypoxic conditions.PI3K pathway inhibitors: potential prospects as adjuncts to vaccine immunotherapy for glioblastoma.Dual mTOR inhibitor MLN0128 suppresses Merkel cell carcinoma (MCC) xenograft tumor growth.MR Studies of Glioblastoma Models Treated with Dual PI3K/mTOR Inhibitor and Temozolomide:Metabolic Changes Are Associated with Enhanced Survival.Recent developments in the treatment of renal cell carcinoma.Genetic variation in the GSTM3 promoter confer risk and prognosis of renal cell carcinoma by reducing gene expression.A novel immunomodulatory molecularly targeted strategy for refractory Hodgkin's lymphomaGremlin promotes retinal pigmentation epithelial (RPE) cell proliferation, migration and VEGF production via activating VEGFR2-Akt-mTORC2 signaling.Targeting angiogenesis in renal cell carcinoma.Preclinical and clinical studies on cytokine-induced killer cells for the treatment of renal cell carcinoma.Pazopanib for the treatment of renal cell carcinoma.Management of poor-risk metastatic renal cell carcinoma: current approaches, the role of temsirolimus and future directions.Gene set enrichment analysis and ingenuity pathway analysis of metastatic clear cell renal cell carcinoma cell line.Dual PI-3 kinase/mTOR inhibition impairs autophagy flux and induces cell death independent of apoptosis and necroptosis.Upregulation of RICTOR gene transcription by the proinflammatory cytokines through NF-κB pathway contributes to the metastasis of renal cell carcinoma.Strategies to overcome therapeutic resistance in renal cell carcinoma.A randomized phase 2 study of MK-2206 versus everolimus in refractory renal cell carcinoma.MCPIP1 contributes to clear cell renal cell carcinomas development.Tumour angiogenesis in Epstein-Barr virus-associated post-transplant smooth muscle tumours.Regulation of spindle and kinetochore-associated protein 1 by antitumor miR-10a-5p in renal cell carcinoma.Chemoprevention for neurofibromatosis 2: just over the horizon?Dual inhibition of BRD4 and PI3K-AKT by SF2523 suppresses human renal cell carcinoma cell growth.Efficacy of PI3K/AKT/mTOR pathway inhibitors for the treatment of advanced solid cancers: A literature-based meta-analysis of 46 randomised control trials.Sunitinib resistance in renal cell carcinoma.Crosstalk between VEGFR and other receptor tyrosine kinases for TKI therapy of metastatic renal cell carcinoma.Novel therapeutic roles of MC-4 in combination with everolimus against advanced renal cell carcinoma by dual targeting of Akt/pyruvate kinase muscle isozyme M2 and mechanistic target of rapamycin complex 1 pathways
P2860
Q26796702-523871DA-72C1-42B9-97AF-C2C6D34E2FE7Q26800216-4FD71C7A-0F45-4717-A7C1-99E728C6D1FAQ27025213-375B001C-F25E-4BBF-AE92-BC573A1CCB4EQ28830269-7CC0249D-47ED-43EB-8EBA-3C927CB6965BQ33442621-0CBCA60C-D2A2-4D81-9EE9-C85714E0007EQ33798469-746F7D04-7901-4BA7-8DFC-9372C25D7530Q34077263-FB58E8C7-958C-4A4E-A465-701A027497B8Q34077272-934C8A8A-AF9B-4FE1-8B20-D88C559ABF08Q34294170-F26E395B-672F-4D3E-B90D-B764F3C1F49AQ35169825-947E0636-3591-42E1-BA09-388AAFA69D42Q35374899-A05CC4EE-5B4A-4F8E-B5D0-B09F57CB76A3Q35835131-BC60559F-9E79-4171-B4EB-44808F82268DQ36086507-D2EEC045-E047-4212-876E-28F698473676Q36916277-98EE7950-C7A5-4268-9335-1EED88078439Q36918102-21398A09-7FE3-476B-9FD7-FE6867CEEC8CQ37300942-BD5DE3DC-5888-4B9A-AB48-B950736A589BQ37385267-DEB0A2FF-8D67-4A2D-971D-830370007839Q37649637-DDAB9A76-F8B2-45B6-936E-C9C0D9E6CB78Q37702395-61C3D147-A6D8-4BA8-B1F5-507F9E16A3E2Q38132231-4DB94680-917F-4A0B-AF48-0ADAE05F5858Q38201328-D85A5943-9810-4E07-98BD-254E391F41C5Q38400468-74DF4FF7-5D69-4D54-88A0-E05CDBC87AD1Q38647604-077CAE7E-E0E8-40F4-A080-84D654B7DCF4Q38765612-B8DBB59B-0BA5-466D-A1B5-3DEADB73A7EEQ38799222-3077070D-F9FA-4D2F-BAB8-9145415A5B7DQ38824994-2E0463CE-5FCA-4D17-ADEA-679AE034AF6EQ39089402-732A28A3-6EA0-4E1D-A54D-1567A380A233Q40397988-3949AB64-1238-48C6-9C46-D10502AA335FQ41022521-421F7166-D439-4FED-B10F-866C736C5ACDQ41880883-08108F66-D1B4-42E0-A8E6-778170284F72Q42288643-8C673C02-1DDA-4ED3-B349-6BD85E806E52Q42408903-71B75340-6A39-495B-BFE0-DB9B8DDE8DC5Q47119388-EC53E3F2-A320-4F73-8EDD-8F9479179330Q48097821-2DBF810B-996B-4183-8181-14EA1E5EF2E0Q51763292-0E36D8BB-802D-4EED-ABC9-D0724D4CF132Q52661758-A3E3F661-8699-4C19-BEC8-0F69DACB4336Q58692208-B8D20A4B-A113-4D9C-8C70-5BA025132DBD
P2860
Targeting PI3K and mTORC2 in metastatic renal cell carcinoma: new strategies for overcoming resistance to VEGFR and mTORC1 inhibitors.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Targeting PI3K and mTORC2 in m ...... o VEGFR and mTORC1 inhibitors.
@en
type
label
Targeting PI3K and mTORC2 in m ...... o VEGFR and mTORC1 inhibitors.
@en
prefLabel
Targeting PI3K and mTORC2 in m ...... o VEGFR and mTORC1 inhibitors.
@en
P2093
P2860
P356
P1476
Targeting PI3K and mTORC2 in m ...... o VEGFR and mTORC1 inhibitors.
@en
P2093
Isabelle Kaufmann
Jillian Brechbiel
Robert A Figlin
P2860
P304
P356
10.1002/IJC.28023
P577
2013-02-12T00:00:00Z